Repros Reports Positive Clinical Data for Vaginal Proellex ® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

2016-04-12 16:01 ET - News Release

  • Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011
  • Proellex®-treated subjects reported a median 100% reduction in diary reports of menstrual bleeding product usage (PBAC)
  • Statistically significant reduction in fibroid size from baseline achieved for the combined active arms compared to increase in fibroid volume in placebo arm, p=0.0437
  • Low dose oral data from a comparable study to be reported in Q2 2016
    Read more: Repros Therapeutics Inc ( RPRX )

Pure Gold Intersects 56.2 g/t Gold Over 1.3 Metres at Russet South, Madsen Gold Project

2016-04-11 06:39 ET - Pure Gold Mining Inc. (TSX VENTURE:PGM) ("Pure Gold" or the "Company") is pleased to announce results from drilling at Russet South located on the Company's 100% owned Madsen Gold Project ("Madsen"). These holes are part of the ongoing 16,000 metre drill program designed to test and build continuity of high grade gold mineralization at Russet South and, as previously reported, within the McVeigh horizon which is in close proximity to the mine infrastructure.

"These exciting new results from Russet South continue to demonstrate the near-surface, high-grade gold endowment of the Madsen Gold Project," said Darin Labrenz, President and CEO of Pure Gold. "Our goal is to unlock the exploration potential of the Madsen Project by concurrently advancing satellite targets such as Russet South, while drill testing the expansion potential of the Madsen Mine mineral resource, as was recently reported on April 4, 2016 from the McVeigh horizon. The presence of high grade gold mineralization at Russet South coupled with a new model for high grade expansion within the McVeigh horizon of the Madsen Mine, provide a compelling exploration opportunity."

Read more: Pure Gold Mining Inc ( PGM )

Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA

-- Single Pivotal Study Needed for Phase 3 --


SEATTLE-- Omeros Corporation (OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that it has initiated its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome (aHUS) after meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros’ lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS. The FDA has awarded OMS721 both orphan drug designation for the treatment of TMAs and fast-track status for the treatment of aHUS.

Read more: Omeros Corporation ( OMER )

Bellerophon Therapeutics Announces Positive Data From the Final Analysis of the Phase 2 Long-Term Extension Study of INOpulse for Treatment of Pulmonary Arterial Hypertension

Long-Term Extension Data Reinforces Earlier Phase 2 Data and Indicates Sustainability of Benefits for PAH Patients

WARREN, N.J., Feb. 09, 2016  -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced positive data from the final analysis of the Company’s Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company’s Phase 2 trial). 

The Phase 2 long-term extension study indicated a sustained benefit to PAH patients who received INOpulse 75 mcg/kg ideal body weight per hour (iNO 75) therapy for at least 12 hours per day combined with Long-Term Oxygen Therapy (LTOT). In Part 1 of the Phase 2 study, these patients showed a mean improvement in 6 minute walk distance (6MWD) of 52.4 meters after 16 weeks of therapy.

Read more: Bellerophon Therapeutics Inc ( BLPH )

Glu Reports Fourth Quarter and Full Year 2015 Financial Results

    Q4 non-GAAP revenue of $57.9 million and Q4 GAAP revenue of $61.0 million
    Q4 Adjusted EBITDA of $2.8 million
    Announced exclusive partnerships with Taylor Swift and Gordon Ramsay
    Approximately 1.3 billion total social followers* of celebrities with whom the company has exclusive partnerships; titles featuring these celebrities expected live by end of 2017
    Investment in and option to acquire Plain Vanilla Corp., developer of hit trivia game QuizUp
    Approved a stock repurchase program to potentially repurchase up to $50 million of Glu’s common stock

SAN FRANCISCO-- Glu Mobile Inc. (GLUU), a leading global developer and publisher of free-to-play games for smartphone and tablet devices, today announced financial results for its fourth quarter and full year ended December 31, 2015.

Read more: Glu Mobile Inc ( GLUU )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker